Forte Biosciences (FBRX) Total Non-Current Liabilities (2016 - 2026)

Forte Biosciences (FBRX) posted quarterly Total Non-Current Liabilities of $23.6 million for Q1 2026, up 13.96% quarter-over-quarter from $20.8 million in Q4 2025.

Forte Biosciences (FBRX) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends

Forte Biosciences (FBRX) has reported Total Non-Current Liabilities for 5 consecutive years, with $23.6 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $23.6 million; the TTM figure through Mar 2026 stood at $23.6 million (changed N/A YoY), while the FY2025 annual figure was $20.8 million, changed N/A from the prior year.
  • Total Non-Current Liabilities grew to $23.6 million in Q1 2026 per FBRX's latest filing, from $20.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $23.6 million in Q1 2026 and bottomed at $20.8 million in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 40.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 1.53 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.88 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.32 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4.20 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 1.17 Bn
10 Forte Biosciences 1.63 Bn 1.28 Bn - 20.29 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 20.29 Mn
Mar 31, 2026 23.65 Mn
Dec 31, 2025 20.75 Mn
Dec 31, 2019 17.23 Mn
Sep 30, 2019 50.87 Mn
Mar 31, 2017 35.74 Mn
Dec 31, 2016 28.23 Mn